NOVO NORDISK A/S-B (NOV.DE) Fundamental Analysis & Valuation

FRA:NOV • DK0062498333

Current stock price

36.228 EUR
+2.22 (+6.54%)
Last:

This NOV.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. NOV.DE Profitability Analysis

1.1 Basic Checks

  • In the past year NOV was profitable.
  • In the past year NOV had a positive cash flow from operations.
  • In the past 5 years NOV has always been profitable.
  • In the past 5 years NOV always reported a positive cash flow from operatings.
NOV.DE Yearly Net Income VS EBIT VS OCF VS FCFNOV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

1.2 Ratios

  • With an excellent Return On Assets value of 18.87%, NOV belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 52.79%, NOV belongs to the top of the industry, outperforming 93.88% of the companies in the same industry.
  • NOV has a Return On Invested Capital of 30.79%. This is amongst the best in the industry. NOV outperforms 95.92% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for NOV is significantly above the industry average of 14.21%.
  • The last Return On Invested Capital (30.79%) for NOV is well below the 3 year average (43.61%), which needs to be investigated, but indicates that NOV had better years and this may not be a problem.
Industry RankSector Rank
ROA 18.87%
ROE 52.79%
ROIC 30.79%
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
NOV.DE Yearly ROA, ROE, ROICNOV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • With an excellent Profit Margin value of 33.14%, NOV belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • In the last couple of years the Profit Margin of NOV has remained more or less at the same level.
  • NOV's Operating Margin of 41.30% is amongst the best of the industry. NOV outperforms 95.92% of its industry peers.
  • NOV's Operating Margin has been stable in the last couple of years.
  • NOV has a better Gross Margin (80.98%) than 85.71% of its industry peers.
  • NOV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 41.3%
PM (TTM) 33.14%
GM 80.98%
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
NOV.DE Yearly Profit, Operating, Gross MarginsNOV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

3

2. NOV.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NOV is creating value.
  • Compared to 1 year ago, NOV has about the same amount of shares outstanding.
  • NOV has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, NOV has a worse debt to assets ratio.
NOV.DE Yearly Shares OutstandingNOV.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B
NOV.DE Yearly Total Debt VS Total AssetsNOV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100B 200B 300B 400B 500B

2.2 Solvency

  • An Altman-Z score of 3.23 indicates that NOV is not in any danger for bankruptcy at the moment.
  • NOV has a Altman-Z score of 3.23. This is comparable to the rest of the industry: NOV outperforms 53.06% of its industry peers.
  • The Debt to FCF ratio of NOV is 4.52, which is a neutral value as it means it would take NOV, 4.52 years of fcf income to pay off all of its debts.
  • NOV has a Debt to FCF ratio (4.52) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.61 indicates that NOV is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.61, NOV is in line with its industry, outperforming 53.06% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 4.52
Altman-Z 3.23
ROIC/WACC4.92
WACC6.26%
NOV.DE Yearly LT Debt VS Equity VS FCFNOV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.3 Liquidity

  • A Current Ratio of 0.80 indicates that NOV may have some problems paying its short term obligations.
  • With a Current ratio value of 0.80, NOV is not doing good in the industry: 81.63% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.57 indicates that NOV may have some problems paying its short term obligations.
  • NOV's Quick ratio of 0.57 is on the low side compared to the rest of the industry. NOV is outperformed by 83.67% of its industry peers.
Industry RankSector Rank
Current Ratio 0.8
Quick Ratio 0.57
NOV.DE Yearly Current Assets VS Current LiabilitesNOV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B 200B

4

3. NOV.DE Growth Analysis

3.1 Past

  • NOV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.77%.
  • NOV shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.66% yearly.
  • NOV shows a small growth in Revenue. In the last year, the Revenue has grown by 6.43%.
  • NOV shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.48% yearly.
EPS 1Y (TTM)1.77%
EPS 3Y23.52%
EPS 5Y20.66%
EPS Q2Q%-4.73%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-7.63%

3.2 Future

  • NOV is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.93% yearly.
  • NOV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.35% yearly.
EPS Next Y-7.2%
EPS Next 2Y-3.65%
EPS Next 3Y0.38%
EPS Next 5Y3.93%
Revenue Next Year-6.27%
Revenue Next 2Y-1.41%
Revenue Next 3Y1.06%
Revenue Next 5Y3.35%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NOV.DE Yearly Revenue VS EstimatesNOV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100B 200B 300B
NOV.DE Yearly EPS VS EstimatesNOV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20 25

5

4. NOV.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • NOV is valuated reasonably with a Price/Earnings ratio of 11.76.
  • 77.55% of the companies in the same industry are more expensive than NOV, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of NOV to the average of the S&P500 Index (26.54), we can say NOV is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 12.67, the valuation of NOV can be described as correct.
  • Based on the Price/Forward Earnings ratio, NOV is valued a bit cheaper than the industry average as 75.51% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 21.68, NOV is valued a bit cheaper.
Industry RankSector Rank
PE 11.76
Fwd PE 12.67
NOV.DE Price Earnings VS Forward Price EarningsNOV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NOV indicates a rather cheap valuation: NOV is cheaper than 91.84% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, NOV is valued a bit more expensive than 63.27% of the companies in the same industry.
Industry RankSector Rank
P/FCF 31.66
EV/EBITDA 6.45
NOV.DE Per share dataNOV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • NOV has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.57
EPS Next 2Y-3.65%
EPS Next 3Y0.38%

7

5. NOV.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 4.74%, NOV is a good candidate for dividend investing.
  • In the last 3 months the price of NOV has falen by -27.15%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • Compared to an average industry Dividend Yield of 1.96, NOV pays a better dividend. On top of this NOV pays more dividend than 83.67% of the companies listed in the same industry.
  • NOV's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 4.74%

5.2 History

  • On average, the dividend of NOV grows each year by 19.05%, which is quite nice.
Dividend Growth(5Y)19.05%
Div Incr Years1
Div Non Decr Years1
NOV.DE Yearly Dividends per shareNOV.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 2026 2 4 6 8 10

5.3 Sustainability

  • NOV pays out 50.53% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • NOV's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP50.53%
EPS Next 2Y-3.65%
EPS Next 3Y0.38%
NOV.DE Yearly Income VS Free CF VS DividendNOV.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B
NOV.DE Dividend Payout.NOV.DE Dividend Payout, showing the Payout Ratio.NOV.DE Dividend Payout.PayoutRetained Earnings

NOV.DE Fundamentals: All Metrics, Ratios and Statistics

NOVO NORDISK A/S-B

FRA:NOV (4/30/2026, 5:29:12 PM)

36.228

+2.22 (+6.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)02-03
Earnings (Next)05-06
Inst Owners31.87%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap122.82B
Revenue(TTM)309.06B
Net Income(TTM)102.43B
Analysts67.57
Price Target42.87 (18.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.74%
Yearly Dividend1.56
Dividend Growth(5Y)19.05%
DP50.53%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.82%
Min EPS beat(2)-7.04%
Max EPS beat(2)1.39%
EPS beat(4)2
Avg EPS beat(4)-0.71%
Min EPS beat(4)-7.04%
Max EPS beat(4)3.94%
EPS beat(8)5
Avg EPS beat(8)1.01%
EPS beat(12)8
Avg EPS beat(12)1.47%
EPS beat(16)11
Avg EPS beat(16)1.68%
Revenue beat(2)1
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)1.07%
Revenue beat(4)1
Avg Revenue beat(4)-0.92%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)1.07%
Revenue beat(8)3
Avg Revenue beat(8)0.15%
Revenue beat(12)6
Avg Revenue beat(12)0.52%
Revenue beat(16)9
Avg Revenue beat(16)0.84%
PT rev (1m)-13.2%
PT rev (3m)-19.72%
EPS NQ rev (1m)10.83%
EPS NQ rev (3m)15.44%
EPS NY rev (1m)-3.37%
EPS NY rev (3m)-6.18%
Revenue NQ rev (1m)2.26%
Revenue NQ rev (3m)-37.39%
Revenue NY rev (1m)-1.7%
Revenue NY rev (3m)-6.51%
Valuation
Industry RankSector Rank
PE 11.76
Fwd PE 12.67
P/S 2.97
P/FCF 31.66
P/OCF 7.71
P/B 4.73
P/tB 14.34
EV/EBITDA 6.45
EPS(TTM)3.08
EY8.5%
EPS(NY)2.86
Fwd EY7.89%
FCF(TTM)1.14
FCFY3.16%
OCF(TTM)4.7
OCFY12.98%
SpS12.2
BVpS7.66
TBVpS2.53
PEG (NY)N/A
PEG (5Y)0.57
Graham Number23.0395 (-36.4%)
Profitability
Industry RankSector Rank
ROA 18.87%
ROE 52.79%
ROCE 39.01%
ROIC 30.79%
ROICexc 33.56%
ROICexgc 59.2%
OM 41.3%
PM (TTM) 33.14%
GM 80.98%
FCFM 9.38%
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
ROICexc(3y)50.94%
ROICexc(5y)53.03%
ROICexgc(3y)100.46%
ROICexgc(5y)105.49%
ROCE(3y)55.75%
ROCE(5y)58.53%
ROICexgc growth 3Y-22.89%
ROICexgc growth 5Y-7.78%
ROICexc growth 3Y-18.13%
ROICexc growth 5Y-11.63%
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
F-Score5
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 4.52
Debt/EBITDA 0.79
Cap/Depr 409.94%
Cap/Sales 29.16%
Interest Coverage 37.34
Cash Conversion 79.59%
Profit Quality 28.3%
Current Ratio 0.8
Quick Ratio 0.57
Altman-Z 3.23
F-Score5
WACC6.26%
ROIC/WACC4.92
Cap/Depr(3y)363.9%
Cap/Depr(5y)282.93%
Cap/Sales(3y)21.19%
Cap/Sales(5y)15.43%
Profit Quality(3y)60.31%
Profit Quality(5y)79.23%
High Growth Momentum
Growth
EPS 1Y (TTM)1.77%
EPS 3Y23.52%
EPS 5Y20.66%
EPS Q2Q%-4.73%
EPS Next Y-7.2%
EPS Next 2Y-3.65%
EPS Next 3Y0.38%
EPS Next 5Y3.93%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-7.63%
Revenue Next Year-6.27%
Revenue Next 2Y-1.41%
Revenue Next 3Y1.06%
Revenue Next 5Y3.35%
EBIT growth 1Y-4.76%
EBIT growth 3Y19.04%
EBIT growth 5Y18.51%
EBIT Next Year8.72%
EBIT Next 3Y6.24%
EBIT Next 5Y8.11%
FCF growth 1Y-58.38%
FCF growth 3Y-23.26%
FCF growth 5Y-0.6%
OCF growth 1Y-1.54%
OCF growth 3Y14.72%
OCF growth 5Y18.05%

NOVO NORDISK A/S-B / NOV.DE Fundamental Analysis FAQ

What is the fundamental rating for NOV stock?

ChartMill assigns a fundamental rating of 6 / 10 to NOV.DE.


Can you provide the valuation status for NOVO NORDISK A/S-B?

ChartMill assigns a valuation rating of 5 / 10 to NOVO NORDISK A/S-B (NOV.DE). This can be considered as Fairly Valued.


How profitable is NOVO NORDISK A/S-B (NOV.DE) stock?

NOVO NORDISK A/S-B (NOV.DE) has a profitability rating of 9 / 10.


What is the financial health of NOVO NORDISK A/S-B (NOV.DE) stock?

The financial health rating of NOVO NORDISK A/S-B (NOV.DE) is 3 / 10.


Can you provide the dividend sustainability for NOV stock?

The dividend rating of NOVO NORDISK A/S-B (NOV.DE) is 7 / 10 and the dividend payout ratio is 50.53%.